drugset / Trial / NCT06790823

Effect of Probiotic Supplement on Improvement of Depressive Symptoms in Patients With Substance-Induced Depressive Disorder

NCT06790823 ↗

Phase 1/2 Completed 40 enrolled Shiraz University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study investigates the potential of probiotics as a therapeutic intervention for Substance-Induced Depressive Disorder (SIDD). The primary question the study aims to answer is: Can a four-week course of probiotics improve depressive symptoms and alter immune markers in patients diagnosed with SIDD, compared to a placebo? The study uses a double-blind, placebo-controlled, randomized clinical trial design with 40 participants to explore this question by measuring clinical outcomes using BDI and HAM-A and immunological markers.

Timeline

Start
2022-07-15
Primary completion
2023-04-12
Completion
2023-04-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moodamin capsuls Unknown 2 unknown —